Shanghai Junshi Biosciences Announces Reorganization
Company Announcements

Shanghai Junshi Biosciences Announces Reorganization

Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.

Shanghai Junshi Biosciences has announced a reorganization involving the sale of about 9.45% equity interest in Shanghai Allink to Allink Hong Kong, and the subscription to a Warrant for a similar equity percentage in Allink Cayman. The deal, valued at RMB 30,597,800, is part of a broader Reorganization Framework Agreement, which is subject to reporting and announcement requirements but exempt from shareholder approval under Hong Kong Listing Rules.

For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App